Megan Sands
CEO
Megan is a seasoned professional in medical devices, pharmaceuticals and Diagnostics. Megan has played pivotal roles in device certification and development for startups in regulated fields. With a passion for women's health innovation combined with experience in the venture capital and startup ecosystems, Megan has driven her role of Chief Operating Officer for Origin Sciences, into a new focus for Ellele Health.
Kiran Kang
Regulatory Affairs Manager
Kiran has worked within the In-vitro Diagnostics industry for over 13 years covering various departments including Manufacturing, Technical Process Development, Technical Services, Quality, and Regulatory. Kiran has extensive experience in Regulatory when it comes to IVD product registrations, technical documentation, layperson (IVDD) CE certification, risk management, and post-market surveillance, as well as building and managing Quality Management Systems to ISO 13485 and ISO 15189.
Neil Ryan
Chief Medical Officer
Alongside his role as CMO, Neil is the RCOG Subspecialty Trainee in Gynaecology Oncology at the Royal Infirmary of Edinburgh and a CSO/NES Clinical Lecturer at the University of Edinburgh. He completed his PhD at the University of Manchester in 2020, leading to changes in NICE guidelines for womb cancer testing. Neil has received numerous awards, including the President's Medal from UoM and the William Blair Bell Lecture from the RCOG. He sits on several prestigious national and international committees and is dedicated to improving personalized treatments and identifying high-risk cancer patients. Neil also serves as a Major in the Royal Army Medical Corps.As Chief Medical Officer for Ellele Health, Neil ensures the company excels while maintaining strict evidence-based practices.
Sue Spencer
Clinical Study Manager
Sue is an experienced Clinical Study Manager with extensive experience working within the Pharmaceutical, medical device and diagnostic Industries. Sue has experience of managing and monitoring across a broad range of studies and therapeutic areas. Sue lead the management of our first feasibility study conducted in Edinburgh,
